Follow-up protocols for patients treated for brain tumours should include regular clinical reviews and appropriate imaging to monitor for recurrence NICE NG99.
For glioma, regular clinical review should be based on residual tumour, life expectancy, patient preferences, previous treatments, and tumour subtype, with more frequent follow-up (every 3 to 6 months) in the first years and then annually or less frequently thereafter NICE NG99.
Routine imaging, such as MRI, should be performed at intervals determined by tumour type and residual disease, with specific schedules for meningioma (e.g., at 3 months, then annually or every 2 years depending on grade) and for incidental meningioma, a scan at 12 months with consideration of discharge if no change NICE NG99.
In cases of suspected recurrence, arrange a clinical review including appropriate imaging, and consider advanced MRI techniques if findings are unclear NICE NG99.
Patients should be informed about the potential for late effects and the importance of ongoing monitoring, especially if they have residual tumour or are at risk of recurrence NICE NG99.